Skip to content


Director Translational Research

Q32 Bio is advancing an integrated portfolio of immunomodulatory therapies. With our protein-based molecules we aim to deliver life-changing treatments for patients with a variety of diseases for whom no, or inadequate, options exist.

Our dynamic, industry-experienced team is growing and we are seeking a candidate to lead our Translational Research (TR) activities.

The candidate should have a strong background in immunology/inflammation and a desire to be part of an energetic, fast-paced company. They will oversee research to establish drug proof of mechanism (POM) in the clinic, assess relevance of target biology to human disease, and develop biomarkers. This work will support clinical development of two current assets – ADX-097, a tissue targeted complement regulator protein and ADX-914, an anti-IL-7R antibody – as well as assets at earlier stages in the Q32 pipeline. The ideal candidate would be an internal thought leader in scientific and disease areas relevant to Q32 Bio programs, as the role has the potential to directly impact clinical trial strategy and design, including patient stratification.

This work will include working closely with cross-functional project teams to discover and implement novel pharmacodynamic and predictive biomarkers and evaluate disease indications for both the ADX-097 and ADX-914 programs. The role will require partnerships with scientists and clinicians in the company and with outside collaborators and CROs to develop capabilities that have the potential to directly impact clinical trial strategy and design, including patient stratification. These efforts will be integrated into the larger clinical development plans for our lead programs. Ideally, the candidate would be an internal thought leader in scientific and disease areas relevant to Q32 Bio programs.

In short, this highly collaborative and strategic role will provide critical contributions to discovery and preclinical projects, provide a critical link between our research and clinical development teams, and have an important strategic role within R&D leadership.


  • Develop program-specific translational strategies that incorporate preclinical research findings to enable proof of mechanism and proof of concept evaluation in clinical trials.
  • Partner with the clinical development team to execute translational biomarker strategies within clinical trial designs to demonstrate proof-of-mechanism in diseases of interest.
  • Actively engage with clinical and research cross-functional teams to prioritize and select disease indications for early and later-stage Q32 Bio programs.
  • Establish external collaborations with KOLs to support our translational strategy, including designing studies using human disease samples and datasets, guiding the analysis and interpretation of results, and integrating the findings into our clinical development plans.
  • Oversee the discovery and implementation of pharmacodynamic and predictive biomarkers for clinical trials.
  • Lead, mentor, and build a talented team of scientists to carry out translational research supporting a pipeline of Q32 Bio assets in immunology and inflammation.


  • PhD or MD/PhD in a scientific discipline and 10+ years industry or related experience
  • A demonstrated record of cutting-edge research in translational immunology and inflammatory diseases (i.e. peer-reviewed publications, grants, research awards, and/or patents).
  • Strong leadership and management experience and excellent oral and written communication skills
  • Experience establishing and managing collaborations with CROs and academic KOLs
  • Familiarity with developing and validating ligand-binding and/or histological assays for use in clinical development is desirable.
  • First-hand experience writing regulatory documents and/or with clinical development a major plus.

Please send Resume and Cover letter to .